Similar companies
Income Statement (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Revenue | 87M | 6% |
| Gross Profit | 32M | 40.8% |
| Cost of Revenue | 55M | 94.2% |
| Operating expense | 42M | 10.5% |
| Net Income | -31M | 146.2% |
| EBITDA | -9.3M | 218.8% |
Balance Sheet (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Total Assets | 364M | 4.9% |
| Total Liabilities | 815M | 4.5% |
| Shares Outstanding | 198M | 0.7% |
Cash Flow (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Cash from operations | -4.3M | 86.4% |
| Cash from financing | 11M | 274.5% |
EPS
Financial Highlights for Esperion Therapeutics in Q3 '25
Esperion Therapeutics reported a revenue of 87M, which is a 6% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 32M, marking a -40.8% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 55M, a 94.2% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 42M, showing a -10.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -31M, showing a -146.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -9.3M, showing a -218.8% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Esperion Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures. A decline in EBITDA signals potential operational challenges or increased costs.
